share_log

F-1: Registration statement for securities of certain foreign private issuers

F-1: Registration statement for securities of certain foreign private issuers

F-1:發行人證券登記表
美股SEC公告 ·  2024/11/20 05:23

Moomoo AI 已提取核心訊息

NeuroSense Therapeutics Ltd. (NeuroSense), a clinical-stage biotechnology company, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on November 19, 2024, for a potential sale of up to 10,000,000 ordinary shares. The shares include 224,697 shares issued as commitment shares to YA II PN, LTD. (YA) under a Standby Equity Purchase Agreement, and up to 9,775,303 additional shares that may be sold to YA over a 36-month period. The agreement allows NeuroSense to sell up to $30 million in ordinary shares to YA, subject to certain limitations. The filing is part of NeuroSense's efforts to raise capital for advancing clinical development of its lead product candidate, PrimeC, for ALS, and for other corporate purposes. The registration statement's effectiveness is pending, and the sale of shares will be subject to market conditions and other factors.
NeuroSense Therapeutics Ltd. (NeuroSense), a clinical-stage biotechnology company, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on November 19, 2024, for a potential sale of up to 10,000,000 ordinary shares. The shares include 224,697 shares issued as commitment shares to YA II PN, LTD. (YA) under a Standby Equity Purchase Agreement, and up to 9,775,303 additional shares that may be sold to YA over a 36-month period. The agreement allows NeuroSense to sell up to $30 million in ordinary shares to YA, subject to certain limitations. The filing is part of NeuroSense's efforts to raise capital for advancing clinical development of its lead product candidate, PrimeC, for ALS, and for other corporate purposes. The registration statement's effectiveness is pending, and the sale of shares will be subject to market conditions and other factors.
NeuroSense Therapeutics Ltd.(NeuroSense)是一家臨床階段的生物技術公司,於2024年11月19日向美國證券交易委員會(SEC)提交了一份註冊聲明,計劃出售多達10,000,000股普通股。該股票包括224,697股根據備選股權購買協議向YA II PN, LTD.(YA)發行的承諾股,以及可能在36個月內出售給YA的多達9,775,303股額外股票。該協議允許NeuroSense向YA出售最多3000萬美元的普通股,但須遵循某些限制。這份申請是NeuroSense爲推進其主要產品候選藥物PrimeC用於ALS的臨床開發,以及其他公司目的而籌集資金的努力的一部分。註冊聲明的有效性尚待確認,股票的出售將受到市場條件和其他因素的影響。
NeuroSense Therapeutics Ltd.(NeuroSense)是一家臨床階段的生物技術公司,於2024年11月19日向美國證券交易委員會(SEC)提交了一份註冊聲明,計劃出售多達10,000,000股普通股。該股票包括224,697股根據備選股權購買協議向YA II PN, LTD.(YA)發行的承諾股,以及可能在36個月內出售給YA的多達9,775,303股額外股票。該協議允許NeuroSense向YA出售最多3000萬美元的普通股,但須遵循某些限制。這份申請是NeuroSense爲推進其主要產品候選藥物PrimeC用於ALS的臨床開發,以及其他公司目的而籌集資金的努力的一部分。註冊聲明的有效性尚待確認,股票的出售將受到市場條件和其他因素的影響。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息